Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
November 04, 2021 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
November 04, 2021 08:00 ET
|
Eyenovia, Inc.
Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK, Nov. 04, 2021 ...
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
October 25, 2021 08:00 ET
|
Eyenovia, Inc.
Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Response Letter...
Eyenovia Reports Second Quarter 2021 Financial Results
August 11, 2021 16:05 ET
|
Eyenovia, Inc.
Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by...
Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
August 04, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia to Participate in Two Upcoming Investor Conferences
July 07, 2021 16:01 ET
|
Eyenovia, Inc.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
June 15, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
May 25, 2021 09:03 ET
|
Eyenovia, Inc.
Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of...
Eyenovia Reports First Quarter 2021 Financial Results
May 12, 2021 16:05 ET
|
Eyenovia, Inc.
MydCombi PDUFA date confirmed for October 28, 2021 Completed patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; top-line data on track for Q2 Secures...
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
May 10, 2021 08:30 ET
|
Eyenovia, Inc.
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...